Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …

Prognosis of non-small cell lung carcinomas (NSCLC) remains poor, especially in advanced
disease. The introduction of new cytotoxic agents in the past decade did only attain minor …

Abstract Purpose of Review Lung cancer remains the leading cause of cancer-related
mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) …

Simple Summary The treatment of advanced and metastatic non-small cell lung cancer
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …

Lung cancer remains the leading cause of malignancy-related mortality worldwide, with over
one million cases diagnosed yearly. Non-small-cell lung cancer (NSCLC) accounts for> …

Therapy for advanced non-small-cell lung cancer has developed significantly with new
awareness of histologic subtype as an important factor in guiding treatment and the …

Lung adenocarcinoma is the most common subtype of lung cancer today. With the discovery
of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) …

Simple Summary The abundance and the dynamic of the studies on NSCLC require
frequent summaries of the current achievements in the field. In our review, we aimed to …

Introduction: Activating mutations of the epidermal growth factor receptor (EGFR) gene and
rearrangement of anaplastic lymphoma kinase (ALK) gene best illustrate the therapeutic …

Background: Lung cancer is the second most common cancer in the United States among
men and women, and it is the most common cause of cancer-related death. Non–small cell …